Alkermes (ALKS) Share-based Compensation (2010 - 2026)
Alkermes' (ALKS) quarterly Share-based Compensation came in at $23.4 million in Q1 2026, down 20.61% year-on-year from $29.5 million in Q1 2025, and down 10.78% on a QoQ basis from $26.3 million in Q4 2025.
Alkermes (ALKS) Share-based Compensation (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Share-based Compensation data on file, last reported at $23.4 million in Q1 2026.
- On a quarterly basis, Share-based Compensation fell 20.61% year-over-year to $23.4 million in Q1 2026; TTM through Mar 2026 was $52.4 million, a 37.95% increase from a year earlier, with the FY2025 full-year figure at $98.7 million, up 205.62% from the prior year.
- Share-based Compensation for Q1 2026 stood at $23.4 million, down from $26.3 million in the prior quarter.
- Over the last five years, Share-based Compensation for ALKS reached as high as $74.8 million in Q4 2023 and fell as low as $344000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $15.3 million across 5 years, with a median of $9.1 million in 2023.
- Across the five-year window, Share-based Compensation sank 99.54% in 2024 and soared 7538.08% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $3.3 million in 2022, then soared by 2167.42% to $74.8 million in 2023, then sank by 99.54% to $344000.0 in 2024, then surged by 7538.08% to $26.3 million in 2025, then dropped by 10.78% to $23.4 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $23.4 million in Q1 2026, $26.3 million in Q4 2025, and $622000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 23.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.44 Mn |
| Mar 31, 2026 | 23.44 Mn |
| Dec 31, 2025 | 26.28 Mn |
| Dec 31, 2025 | 26.28 Mn |
| Sep 30, 2025 | 622,000.00 |
| Sep 30, 2025 | 622,000.00 |
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 344,000.00 |
| Dec 31, 2024 | 344,000.00 |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Dec 31, 2023 | 74.83 Mn |
| Dec 31, 2023 | 74.83 Mn |